Evidence map›Paper›PMID 36647687›Full record

ArticleAlimentary pharmacology & therapeutics2023

Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis.

Mazen Noureddin, Zachary Goodman, Dean Tai, Elaine L K Chng, Yayun Ren, Pol Boudes, Harold Shlevin, Guadalupe Garcia-Tsao, Stephen A Harrison, Naga P Chalasani

Open access · hybridAbstract read
In one paragraph

Article in Alimentary pharmacology & therapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 20 citations in OpenAlex.

  1. Digital quantitation of bridging fibrosis and septa reveals changes in natural history and treatment not seen with conventional histology.Liver international : official journal of the International Association for the Study of the Liver · 2024
    Trial
  2. [Non-invasive evaluation and prediction of portal hypertension: focusing on disease progression and outcome].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025
    Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 2 countries.

Mazen NoureddinHouston Methodist Hospital and Houston Research Institute, Houston, Texas, USA.ORCID 0000-0003-2127-2040
Zachary GoodmanInova Fairfax Hospital, Falls Church, Virginia, USA.
Dean TaiHistoIndex Pte. Ltd., Singapore, Singapore.
Elaine L K ChngHistoIndex Pte. Ltd., Singapore, Singapore.
Yayun RenHistoIndex Pte. Ltd., Singapore, Singapore.
Pol BoudesGalectin Therapeutics Inc., Norcross, USA.
Harold ShlevinGalectin Therapeutics Inc., Norcross, USA.
Guadalupe Garcia-TsaoSection of Digestive Diseases, Yale University and CT-VA Healthcare System, New Haven, Connecticut, USA.ORCID 0000-0001-8371-4524
Stephen A HarrisonPinnacle Clinical Research, San Antonio, Texas, USA.
Naga P ChalasaniDivision of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID 0000-0003-4082-3178
Histoindex (Singapore) · SGRodin Therapeutics (United States) · USHouston Methodist · USIndiana University School of MedicineInova Fairfax Hospital · USPinnacle Clinical Research · USYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsIn cirrhotic nonalcoholic steatohepatitis (NASH) clinical trials, primary efficacy endpoints have been hepatic venous pressure gradient (HVPG), liver histology and clinical liver outcomes. Important histologic features, such as septa thickness, nodules features and fibrosis area have not been included in the histologic assessment and may have important clinical relevance. We assessed these features with a machine learning (ML) model.

methodsNASH patients with compensated cirrhosis and HVPG ≥6 mm Hg (n = 143) from the Belapectin phase 2b trial were studied. Liver biopsies, HVPG measurements and upper endoscopies were performed at baseline and at end of treatment (EOT). A second harmonic generation/two-photon excitation fluorescence provided an automated quantitative assessment of septa, nodules and fibrosis (SNOF). We created ML scores and tested their association with HVPG, clinically significant HVPG (≥10 mm Hg) and the presence of varices (SNOF-V).

resultsWe derived 448 histologic variables (243 related to septa, 21 related to nodules and 184 related to fibrosis). The SNOF score (≥11.78) reliably distinguished CSPH at baseline and in the validation cohort (baseline + EOT) [AUC = 0.85 and 0.74, respectively]. The SNOF-V score (≥0.57) distinguished the presence of varices at baseline and in the same validation cohort [AUC = 0.86 and 0.73, respectively]. Finally, the SNOF-C score differentiated those who had >20% change in HVPG against those who did not, with an AUROC of 0.89.

conclusionThe ML algorithm accurately predicted HVPG, CSPH, the development of varices and HVPG changes in patients with NASH cirrhosis. The use of ML histology model in NASH cirrhosis trials may improve the assessment of key outcome changes.

Indexed as

Hypertension, PortalNon-alcoholic Fatty Liver DiseaseVaricose VeinsFibrosisHumansLiverLiver CirrhosisPortal Pressure

Identifiers

PMID36647687
PMCPMC10107331
OpenAlexW4316673060

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.